C-Path and NORD collaborate to establish rare disease data platform

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ipopba)
(Image: Getty/ipopba)

Related tags: Rare disease, Data, analytics, Clinical trial, Clinical trial design

The Critical Path Institute and National Organization for Rare Disorders are developing a new data and analytics platform to inform clinical trial design and advance therapies for rare diseases.

Funded by a cooperative agreement with the US Food and Drug Administration (FDA), the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) will be created with Critical Path Institute (C-Path) and the National Organization for Rare Disorders (NORD).

Peter Saltonstall, president and CEO of NORD, stated that there are more than 25 million people in the US affected by one or more rare diseases, of which there are 7,000 known.

RDCA-DAP includes integrated rare disease data from sources such as clinical trials, observational studies, real-world data (RWD), and patient registries. NORD’s IAMRARE registry platform, focused on analytics, also will be included within the collaborative platform, which will help the organizations find and address knowledge gaps.

Joseph Scheeren, president and CEO of C-path stated, “By leveraging the rare disease community access and data of NORD and the data curation, aggregation, governance, and advanced analytics expertise of C-Path, we are poised to make a significant impact on rare disease drug development by providing quality data that will inform clinical trial design and accelerate the development of therapies.”

NORD and C-Path will use the knowledge of the natural course of disease established through the platform to determine an approach for clinical trial readiness, evaluate new treatments, and generate solutions to inform clinical trial design and regulatory review.

“Drug development for these diseases is often impeded due to the low affected patient numbers and a limited understanding of how rare diseases progress or how to measure clinical improvements. FDA-approved treatments exist for only 10% of rare diseases; with this collaboration we can change that statistic for the better for our rare community,”​ said Scheeren.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us

Products

View more

Webinars